GRI Bio (GRI) Stock Price, News & Analysis

Company Overview

GRI Bio, Inc. (NASDAQ: GRI) is a clinical-stage biotechnology company focused on developing therapies that modulate natural killer T (NKT) cells. NKT cells are immune cells involved in regulating inflammation and immune responses, and the company is researching their potential role in autoimmune, inflammatory, and fibrotic diseases.

GRI Bio’s lead product candidate is GRI-0621, an orally administered small-molecule inhibitor designed to selectively modulate type I NKT cells. The company has been evaluating GRI-0621 as a potential treatment for idiopathic pulmonary fibrosis, a progressive lung disease characterized by scarring and impaired respiratory function. GRI Bio is also advancing additional NKT-cell-focused compounds, including GRI-0633, for potential use in other immune-mediated conditions.

The company’s development programs are based on research intended to identify how NKT-cell activity contributes to disease and whether targeted modulation can provide therapeutic benefits. GRI Bio is headquartered in the United States and is focused primarily on advancing its pipeline through clinical development and potential strategic partnerships. Information about the company’s current leadership and broader commercial operations is limited publicly.

Key Stats

• Today's Range: $1.72 to $1.83
• 50-Day Range: $1.38 to $2.88
• 52-Week Range: $1.36 to $64.12
• Volume: 12,346 shs
• Average Volume: 233,210 shs
• Market Capitalization: $3.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Hold

GRI Bio Stock Analysis - MarketRank™

GRI Bio scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

GRI Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

GRI Bio has a consensus price target of $21.00, representing about 1,053.8% upside from its current price of $1.82.

Amount of Analyst Coverage

GRI Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GRI Bio are expected to grow in the coming year, from ($3.75) to ($2.00) per share.

Price to Book Value per Share Ratio

GRI Bio has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.06% of the float of GRI Bio has been sold short.

Short Interest Ratio / Days to Cover

GRI Bio has a short interest ratio ("days to cover") of 1.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GRI Bio has recently increased by 0.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GRI Bio does not currently pay a dividend.

Dividend Growth

GRI Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

GRI Bio has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for GRI Bio this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for GRI on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GRI Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.61% of the stock of GRI Bio is held by insiders.

Percentage Held by Institutions

33.95% of the stock of GRI Bio is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/13/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:GRI
• Previous Symbol: NASDAQ:VLON
• CIK: 1824293
• Web: www.gribio.com
• Phone: 267-607-8255
• Fax: N/A
• Employees: 5
• Year Founded: 2009

Price Target and Rating

• Average Price Target for GRI Bio: $21.00
• High Price Target: $32.00
• Low Price Target: $10.00
• Potential Upside/Downside: +1,085.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($38.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -134.03%
• Return on Assets: -106.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.30
• Quick Ratio: 10.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.16 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 2,190,000
• Free Float: 2,173,000
• Market Cap: $3.88 million
• Optionable: Not Optionable
• Beta: -1.13